Dr Robert Glynne-Jones is Consultant Clinical Oncologist at Mount Vernon Hospital, Watford and Barnet General Hospitals in London, where he is the Macmillan Lead Clinician in Gastrointestinal and Colorectal Cancer.
Dr Glynne-Jones is also Chief Medical Advisor to the national UK charity Bowel Cancer UK, and has a major interest in communications skills and patient choice.
He is a member of the European Society for Therapeutic Radiology and Oncology, the EORTC, ESMO and the American Society of Clinical Oncology. He plays an active role in the UK NCRI colorectal research group.
In the past he has been a member of NICE committees responsible for guidance for colorectal cancer and for producing quality standards for colorectal cancer, and is currently a member of a NICE committee examining Lynch syndrome and mismatch repair testing.
His major research interest is in rectal and anal cancer and in phase I, and translational research in chemoradiation.
He has more than 150 peer reviewed publications.
Current areas of research include the integration of immune checkpoint inhibitors into chemoradiation schedules in anal cancer and rectal cancer, the investigation of predictive factors for response and resistance to chemoradiation in anal and rectal cancer, DCE-MRI changes, and the optimal timing for surgery after chemoradiation.
Selected publications from PubMed
Histological assessment of radiotherapy-induced injury in the anal canal: an exploratory study.
Leventi A, Sibbons P, Tsigka A, Korkolis D, Peponi E, Skafida Ε, Moorghen M, Vaizey CJ, Glynne-Jones R, Maeda Y
Int J Colorectal Dis. 2025 Dec 3;40(1):246 doi: 10.1007/s00384-025-05027-0.
Prevalence of nodal involvement in rectal cancer after chemoradiotherapy.
Haak HE, Beets GL, Peeters K, Nelemans PJ, Valentini V, Rödel C, Kuo L, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Pucciarelli S, Suarez J, Theodoropoulos G, Biondo S, Lambregts DMJ, Beets-Tan RGH, Maas M
Br J Surg. 2021 Oct 23;108(10):1251-1258 doi: 10.1093/bjs/znab194.
The Management and Prevention of Anal Squamous Cell Carcinoma.
Eng C, Messick C, Glynne-Jones R
Am Soc Clin Oncol Educ Book. 2019 Jan;39:216-225 doi: 10.1200/EDBK_237433.
Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up.
Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D, European Society for Medical Oncology (ESMO), European Society of Surgical Oncology (ESSO), European Society of Radiotherapy and Oncology (ESTRO)
Eur J Surg Oncol. 2014 Oct;40(10):1165-76 doi: 10.1016/j.ejso.2014.07.030.
In the introduction, Richard Heald, a world-renowned specialist in rectal cancer surgery, highlighted, among other things, the importance of the transanal technique, the progress that it represents in low rectal cancer, and its benefits in certain cases due to specific pelvic anatomy. Steven Wexner, the Head of the Digestive Disease Center and Colorectal surgery department at the Cleveland Clinic, chaired the following presentations and debates in which a group of expert gastroenterologists and radiologists discussed the guidelines to follow for diagnosis and tumor staging, covering the following topics: The importance of colonoscopy, the distance from the tumor to the anal verge, rigid rectoscopy and controversies in endoscopic tattooing. Staging according to the MRI and USE and the comparison between them Correct assessment for neoadjuvant treatment As well as the functional explanations required before and after rectal cancer surgery. Later Antoni Castells, Head of the Clinic Institute of Digestive and Metabolic Disease (ICMDM) at the Hospital Clinic in Barcelona, examined, together with the oncologists Cristina Nadal (Hospital Clinic) and Robert Glynne-Jones (Mount Vernon Cancer Center) the various chemotherapy and preoperative radiotherapy options in rectal cancer, as well as which treatment should be selected and why, and the current trends based on the latest studies at the European and global level. Then a live surgery was performed: a Cecil approach to rectal cancer. Joep Knol (Belgium) and Patricia Sylla (United States) provided a step-by-step description of the procedure. While the surgery was being performed by Antonio Lacy and his team, the experts commented on several matters, such as technical considerations, main steps and some controversies regarding the operation. Meanwhile, they received queries from online viewers which were answered from the main set and from the operating theatre. After removing the surgical specimen, the pathologists Maria Cuatrecasas (Hospital Clinic), Mariana Berho (Cleveland Clinic) and Philip Quirke (United Kingdom) proceeded to perform the initial analysis of the specimen in the operating room, focusing on the characteristics and quality of the mesorectum. After surgery other topics of interest were discussed, such as Routine Genetic Counseling for Rectal Cancer Patients by Francesc Balaguer (Hospital Clinic), postoperative treatment based on pre-op staging vs pathological examination by Jaume Capdevila (Vall d’ Hebron) and finally the pathology audit regarding the standardisation of pathological evaluation, the surgical margin and molecular lymph node assessment. Finally Steven Wexner made some final statements and spoke about the importance of training for TaTME and its key elements. Richard Heald and Antonio Lacy then made the closing remarks, bringing the event to its end.
Published
Jan 2016
Treatment for rectal cancer patients is constantly evolving towards a highly tailored approach. An updated and multidisciplinary team of specialists should work together in order to achieve this. The goal is to offer the best treatment with the lowest toxicity rate. In this lecture, Robert Glynne-Jones from the Barnet Hospital talks about several issues regarding preoperative QRD for patients with clinical stage II/III rectal cancer. Among other things, he explains the importance of standardization regarding: Short course vs long course therapy Patients selection criteria International Guidelines
Published
May 2015
Help your network discover Dr. Robert Glynne Jones's clinical expertise.
